Please login to the form below

Not currently logged in

Galapagos expands presence in fibrosis, NASH with Evotec deal

As lead candidate filgotinib nears filing, firm looks to expand horizons


Fatty liver disease NASH and other fibrosis-related conditions are seen as biopharma’s ‘next big thing’ and Galapagos has just announced a second investment in two months in the field.

The company based in Mechelen, Belgium looks set to break into the big time this year, thanks to its JAK 1 selective inhibitor filgotinib, a new RA treatment co-developed with Gilead which promises to be a blockbuster if it gains approval in 2019/2020 as expected.

Now the firm is looking to expand and build up its own presence in fibrosis, where last month it acquired a candidate in phase 2 and phase 3 trials for fibrosis/IPF.

It has announced an in-licensing deal with drug discovery specialists Evotec, centered on a small molecule currently in its pre-clinical pipeline which could treat fibrotic diseases and NASH.

The Germany-headquartered firm uses its in-house assay development and drug screening capabilities to identify small molecule modulators against the target, which remains undisclosed.

In exchange for global commercialisation rights to Galapagos, Evotec receives an upfront payment and is eligible for potential milestone and royalty payments. Galapagos will be responsible for all further development of the programme. Galapagos will have access to specific screening formats at Evotec to support the final pre-clinical development.

Galapagos acquired its IPF/fibrosis candidate in a deal with Fibrocor Therapeutics, a privately held Canadian company.


Piet Wigerinck

"Following the Fibrocor deal announced early January, the collaboration with Evotec announced today again underlines our commitment to expanding our fibrosis franchise", said Dr Piet Wigerinck, chief scientific officer of Galapagos. "We highly regard the scientific know-how of Evotec, and are hence very much looking forward to collaborating with the team."

Article by
Andrew McConaghie

7th February 2019

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Grace Communications

Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...